Surrey Heartlands

Joint Formulary & PAD

Colistimethate sodium - Bronchiectasis

You are here : Home > Formulary Search > Colistimethate sodium - Bronchiectasis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Powder
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
Off Label
R
SPC
Restrictions / Comments :
Important

Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialisit microbiology recommendation. Colistimethate sodium 1million unit powder for solution for injection, infusion, inhalation vials is the most cost effective option for inhalation use by nebulisation.

Documents :
 
Shared Care
Colistimethate nebulised shared care protocol.docx

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Colistimethate sodium
Indication :
Bronchiectasis
Group Name :
Keywords :
nebuliser, nebules, Home nebuliser, antibiotic, antibacterial
Brand Names Include :
Colomycin
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

06 Oct 26 - Surrey & Sussex Area Prescribing Committee (APC)

The Surrey & Sussex APC approved the shared care protocol for nebulised colistimethate sodium (Colomycin®) for adults with non-cystic fibrosis bronchiectasis.

This supports the Surrey Heartlands APC decision in March 2026 to change the traffic light status from Blue to Amber noting that nebulised colistimethate sodium is used off-label for non-cystic fibrosis bronchiectasis patients, with complex respiratory needs, who remain under specialist care.

 

Other Indications

Below are listed other indications that Colistimethate sodium is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Bronchiectasis.

  • No records returned.